Brought to you by 
Novartis, Anadys end toll-like receptor deal
Jun 2005
Executive Summary
Just one day after signing an agreement with Hybridon, Novartis has signed another toll-like receptor (TLR) deal, this time with Anadys Pharmaceuticals (developing therapeutics for infectious and viral diseases). Novartis gets the exclusive worldwide development, manufacturing, and marketing rights to Anadys's ANA975 and other toll-like receptor 7 oral prodrugs for chronic hepatitis B and C viruses and other infectious diseases.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Includes Royalty or Profit Split Information
- Co-Promotion
- Includes Contract
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis, Anadys end toll-like receptor deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice